Demystifying the Disinfectant Label
This Webinar sponsored by PDI and presented by Hudson Garrett provides an overview of EPA-registered disinfectant product labels and explores broad-spectrum efficacy claims, disinfectant contact time, regulatory requirements for compliance with EPA FIFRA regulation, as well as the imperative
www.infectioncontroltoday.com/webinars/2012/06/demystifying-the-disinfectant-label.aspx - 61k
2011-09-20 - Making Sense of Disinfectant Labels A Step By Step Approach
including: Understanding product labels, evaluating broad-spectrum efficacy claims, adhering to overall
www.infectioncontroltoday.com/articles/2011/09/making-sense-of-disinfectant-labels-a-step-by-step-approach.aspx - 54k
Exploring the Science Behind Antimicrobial Products & Technologies
about the science behind labelclaims and marketing hype, including the FDA clearance and EPA...Manufacturers make claims about their products' efficacy in killing disease-causing pathogens, but what do infection preventionists really know about the validity of these claims? In a series
www.infectioncontroltoday.com/library/2011/07/ict-ds-2010-12.aspx - 50k
Exploring the Science Behind Antimicrobial Products & Technologies
about the science behind labelclaims and marketing hype, including the FDA clearance and EPA...Manufacturers make claims about their products' efficacy in killing disease-causing pathogens, but what do infection preventionists really know about the validity of these claims? In a series
www.infectioncontroltoday.com/library/2011/07/ict-ds-2010-12.aspx?topic=disinfection-and-sterilization - 52k
2011-04-20 - FDA Warns Companies to Stop Making MRSA Claims for OTC Products
The Food and Drug Administration (FDA) has issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus (MRSA).
www.infectioncontroltoday.com/news/2011/04/fda-warns-companies-to-stop-making-mrsa-claims-for-otc-products.aspx - 47k
2011-04-20 - Hand Sanitizers Carry Unproven Claims to Prevent MRSA Infections
Some hand sanitizers and antiseptic products come with claims that they can prevent methicillin-resistant Staphylococcus aureus (MRSA) infections. The Food and Drug Administration (FDA) says these statements are unproven.
www.infectioncontroltoday.com/news/2011/04/hand-sanitizers-carry-unproven-claims-to-prevent-mrsa-infections.aspx - 46k
2012-10-25 - Sani-Cloth Bleach Receives EPA Registration for Clostridium difficile Claim in All 50 States
Sani-Cloth® Bleach Germicidal Disposable Wipe from PDI Healthcare has received Environmental Protection Agency (EPA) registration for its Clostridium difficile (C. diff) claim in all 50 states. Healthcare facilities nationwide can now benefit from the full Sani-Cloth® Environmental Hygiene System
www.infectioncontroltoday.com/news/2012/10/sanicloth-bleach-receives-epa-registration-for-clostridium-difficile-claim-in-all-50-states.aspx - 46k
2013-03-08 - FDA Issues Draft Guidance for Manufacturers to Label Products Not Made with Natural Rubber Latex
The Food and Drug Administration (FDA) today issued draft recommendations to medical product manufacturers for providing consumers with accurate information about products that are not made with natural rubber latex (NRL).
www.infectioncontroltoday.com/news/2013/03/fda-issues-draft-guidance-for-manufacturers-to-label-products-not-made-with-natural-rubber-latex.aspx - 45k
2012-09-04 - Claims Data Lacks Accuracy, Consistency Needed to Inform Nonpayment or Hospital Comparisons
The Centers for Medicare & Medicaid Services (CMS) limits payment for key "preventable" complicating conditions acquired during hospital stay. The claims data is used to deny payment, and the data is reported publicly so that hospitals can be compared by complication rate.
www.infectioncontroltoday.com/news/2012/09/claims-data-lacks-accuracy-consistency-needed-to-inform-nonpayment-or-hospital-comparisons.aspx - 45k
2012-11-06 - FDA Warns Tennessee Firm About Claims for Fungal Meningitis, MRSA, Lyme Disease
The Food and Drug Administration (FDA) today issued a warning letter to The Avalon Effect Inc., a company based in Franklin, Tenn., for its marketing of a light therapy product that claims to cure or treat symptoms of fungal meningitis, methicillin-resistant Staphylococcus aureus (MRSA
www.infectioncontroltoday.com/news/2012/11/fda-warns-tennessee-firm-about-claims-for-fungal-meningitis-mrsa-lyme-disease.aspx - 44k
